PR Newswire Clinical TrialsOriginal article
TranspireBio Announces Successful Completion of a Pivotal Phase 1 Study with its Proprietary Springboard™ Soft Mist Inhaler Platform
Phase 1positiveSpringboard™ Soft Mist Inhaler PlatformPositive
AI Analysis
Summary
TranspireBio Holdings Inc. announced successful completion of a pivotal Phase 1 pharmacokinetic study for its Springboard™ Soft Mist Inhaler Platform designed for respiratory and systemic diseases. The positive Phase 1 outcome represents progress for the company's inhaled therapeutics development program.
Clinical Trial Data
Phase
Phase 1
Primary Endpoint
Met
Outcome Details
Successful completion of pivotal Phase 1 pharmacokinetic study
Importance:6/10
Sentiment:
0.75
inhaled therapeuticsclinical-stageplatform technologypharmacokinetic study
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 6, 2026 11:15 AM